Improving outcomes in sepsis caused by Gram-negative bacteria using targeted nanotherapeutics
Targeting Both Hyperinflammation and Pyroptosis Via Nanotherapeutics to Improve Outcomes in Gram-Negative Sepsis
This study is testing a new treatment using tiny particles to help people with sepsis, a serious condition caused by infections, by reducing harmful inflammation and improving their immune response to help them recover better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project ID | NIH-10998520 on NIH RePORTER |
What this research studies
This research focuses on sepsis, a severe condition caused by infections that leads to an uncontrolled immune response. The study aims to develop a new treatment using nanoparticles that can target both the excessive inflammation and cell death associated with sepsis. By using innovative immune-modulating nanoparticles, the research seeks to reduce the harmful effects of a cytokine storm and improve the immune response in patients suffering from Gram-negative bacterial infections. This approach is designed to enhance patient recovery and prevent long-term complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with sepsis caused by Gram-negative bacterial infections.
Not a fit: Patients with sepsis caused by Gram-positive bacteria or other non-bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves recovery outcomes for patients with sepsis.
How similar studies have performed: While the approach of using nanoparticles for immune modulation is innovative, similar strategies targeting inflammation in sepsis have shown promise in preliminary studies.
Where this research is happening
Syracuse, United States
- Upstate Medical University — Syracuse, United States (Active)
Researchers
- Principal investigator: Messina, Jennifer M — Upstate Medical University
- Study coordinator: Messina, Jennifer M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.